Table 2.
Selected baseline characteristics of randomized participants
| China | Europe | All | |
|---|---|---|---|
| Number randomized | 10 932 | 14 741 | 25 673 |
| Mean age (SD) | 63.4 (7.6) | 65.9 (7.2) | 64.9 (7.5) |
| Male (%) | 8680 (79.4%) | 12 549 (85.1%) | 21 229 (82.7%) |
| History | |||
| Coronary disease | 8407 (76.9%) | 11 730 (79.6%) | 20 137 (78.4%) |
| Cerebrovascular disease | 4462 (40.8%) | 3708 (25.2%) | 8170 (31.8%) |
| Peripheral arterial disease | 508 (4.6%) | 2706 (18.4%) | 3214 (12.5%) |
| Diabetes mellitusa | 4611 (42.2%) | 3688 (25.0%) | 8299 (32.3%) |
| Treated hypertension | 6894 (63.1%) | 9025 (61.2%) | 15 919 (62.0%) |
| Smoking status | |||
| Never | 4197 (38.4%) | 4529 (30.7%) | 8726 (34.0%) |
| Former | 4248 (38.9%) | 8089 (54.9%) | 12 337 (48.1%) |
| Current | 2487 (22.7%) | 2123 (14.4%) | 4610 (18.0%) |
| Alcohol intake (units/week) | |||
| None | 9516 (87.0%) | 5669 (38.5%) | 15 185 (59.1%) |
| >0 <21 | 1243 (11.4%) | 7780 (52.8%) | 9023 (35.1%) |
| ≥21 | 173 (1.6%) | 1292 (8.8%) | 1465 (5.7%) |
| Physical measurements | |||
| Mean systolic blood pressure (mmHg) (SD) | 142.8 (22.4) | 144.1 (20.1) | 143.5 (21.1) |
| Mean diastolic blood pressure (mmHg) (SD) | 79.9 (12.2) | 81.1 (10.7) | 80.6 (11.4) |
| Mean body mass index (kg/m2) (SD) | 26.2 (3.3) | 28.8 (5.0) | 27.7 (4.5) |
| Medications | |||
| Current statin use (years) | |||
| None | 5625 (51.5%) | 566 (3.8%) | 6191 (24.1%) |
| >0 <3 | 4339 (39.7%) | 3811 (25.9%) | 8150 (31.7%) |
| ≥3 | 968 (8.9%) | 10 364 (70.3%) | 11 332 (44.1%) |
| Study LDL-lowering therapy (daily) | |||
| Simvastatin 40 mg | 8051 (73.6%) | 5491 (37.2%) | 13 542 (52.7%) |
| Ezetimibe/simvastatin 10/40 mg | 2881 (26.4%) | 9250 (62.8%) | 12 131 (47.3%) |
| Non-study medications | |||
| Aspirin | 9417 (86.1%) | 12 742 (86.4%) | 22 159 (86.3%) |
| Other antiplatelet | 1910 (17.5%) | 2727 (18.5%) | 4637 (18.1%) |
| ACEi or ARBb | 4657 (42.6%) | 10 090 (68.4%) | 14 747 (57.4%) |
| Diuretic | 969 (8.9%) | 3750 (25.4%) | 4719 (18.4%) |
| Calcium channel blocker | 3454 (31.6%) | 3638 (24.7%) | 7092 (27.6%) |
| Beta blocker | 5635 (51.5%) | 9495 (64.4%) | 15 130 (58.9%) |
aSelf-reported, or baseline plasma glucose ≥ 11.1 mmol/L if fasted <8 h or ≥7.0 mmol/L if fasted ≥8 h, or baseline HbA1c ≥48 mmol/mol, or use of hypoglycaemic medication at randomization.
bAngiotensin-converting enzyme inhibitor (ACEi) or angiotensin-2 receptor blocker (ARB).